Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

MicroRNAs may play a key role in future medicine

Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled "MicroRNAs: A Potential New Frontier for Medicine," an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.

24 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Research roundup: Successful medical homes; shortage of HIV doctors; boosting use of $4 generic drugs

Every Friday, Jennifer Evans compiles this selection of recently-released health policy studies and briefs.

19 Mar 2011

Cognitive impairment may not be fully reversible in patients with liver disease: Study

There are potential legal ramifications for physicians of patients who drive with cognitive impairment, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

19 Mar 2011

Scientists discover enzyme family that plays a crucial role in regulating cell motility

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that members of an enzyme family found in humans and throughout the plant and animal kingdoms play a crucial role in regulating cell motility. Their findings suggest an entirely new strategy for treating conditions ranging from diabetic ulcers to metastatic cancer.

19 Mar 2011

Hospitals with higher diagnosis frequency for chronic conditions have lower case-fatality rate

An examination of data for more than 5 million Medicare beneficiaries finds that hospital regions that have a greater frequency of diagnoses have a lower case-fatality rate for chronic conditions such as coronary artery disease and kidney failure, according to a study in the March 16 issue of JAMA.

16 Mar 2011

Study underscores need for monitoring vitamin D levels in all cirrhosis patients

Vitamin D deficiency is a well reported complication in chronic cholestatic liver disease such as primary biliary cirrhosis. While the prevalence and treatment of this deficiency has been addressed in many articles over the last decades, little is known of the vitamin D status in alcoholic liver cirrhosis.

16 Mar 2011

iTherX commences ITX-5061 Phase 1b study in patients with HCV

iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection.

16 Mar 2011

Bariatric surgery can lead to long-term weight loss, reduce cardiac risk factors in obese adults

Bariatric surgery can result in long-term weight loss and significant reductions in cardiac and other risk factors for some severely obese adults, according to a scientific statement from the American Heart Association.

15 Mar 2011

EASL schedules press conference and news briefings during International Liver Congress 2011

The EASL International Liver Congress is an opportunity for over 6,000 clinicians and scientists from around the world to hear the latest research, perspectives and treatments for liver diseases from principal experts in the field. It features a high-calibre and multi-disciplinary scientific programme covering groundbreaking information and in-depth examination of the most essential topics.

14 Mar 2011

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.

14 Mar 2011

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Researchers have provided new clues into the genetics underlying a chronic form of liver disease, called primary biliary cirrhosis, which can lead to transplant surgery for patients.

14 Mar 2011

Scientists discover four new genetic variants in humans linked with NAFLD

Five genetic variants in humans - four new - associate with Nonalcoholic Fatty Liver Disease, according to a study published March 10 in PLoS Genetics.

10 Mar 2011

Study: Alcohol abuse impacts quality of life for patients after liver transplant

A history of alcohol abuse significantly impacts quality of life for patients after liver transplant, according to researchers at Henry Ford Hospital.

10 Mar 2011

NovaShunt raises Series B financing for CHF 23.7 million

NovaShunt AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23.7 million in a Series B preferred share financing round co-led by BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund.

9 Mar 2011

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex Pharmaceuticals Incorporated announced today that 15 abstracts on the company's medicines in development for hepatitis C, including its protease inhibitor, telaprevir, and polymerase inhibitor, VX-222, were accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver in Berlin, Germany, March 30 to April 3, 2011.

9 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Study: HBV infection reduces risk of liver metastasis in CRC patients

Colorectal cancer is the second leading cause of cancer-related deaths in Western countries. Metastatic liver disease more frequently develops metachronous metastasis following treatment of CRC.

9 Mar 2011

BMY to present new Phase II data on investigational hepatitis C compounds at ILC

New Phase II data on multiple Bristol-Myers Squibb Company investigational hepatitis C compounds will be presented at The International Liver Congress, the 46th annual meeting of the European Association for the Study of the Liver in Berlin, Germany, from March 30 to April 2.

8 Mar 2011

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

A major new clinical trial seeks to determine whether HIV-infected asymptomatic individuals have less risk of developing AIDS or other serious illness if they begin taking antiretrovirals sooner rather than later, based on their level of CD4+ T-cells.

8 Mar 2011

Liver Disease News and Research

Further Reading

MicroRNAs may play a key role in future medicine

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Research roundup: Successful medical homes; shortage of HIV doctors; boosting use of $4 generic drugs

Cognitive impairment may not be fully reversible in patients with liver disease: Study

Scientists discover enzyme family that plays a crucial role in regulating cell motility

Hospitals with higher diagnosis frequency for chronic conditions have lower case-fatality rate

Study underscores need for monitoring vitamin D levels in all cirrhosis patients

iTherX commences ITX-5061 Phase 1b study in patients with HCV

Bariatric surgery can lead to long-term weight loss, reduce cardiac risk factors in obese adults

EASL schedules press conference and news briefings during International Liver Congress 2011

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Scientists discover four new genetic variants in humans linked with NAFLD

Study: Alcohol abuse impacts quality of life for patients after liver transplant

NovaShunt raises Series B financing for CHF 23.7 million

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Study: HBV infection reduces risk of liver metastasis in CRC patients

BMY to present new Phase II data on investigational hepatitis C compounds at ILC

New clinical trial to assess antiretroviral treatment in HIV-infected individuals based on CD4 counts

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News